(Q38207153)

31 August 2017

Emerging therapeutic interventions for idiopathic pulmonary fibrosis (English)

1 reference

31 August 2017

1 reference

Sushmita Chakraborty

1

1 reference

ORCID Public Data File 2021

author name string

Puneet Chopra

2

1 reference

31 August 2017

Senthil V Ambi

3

1 reference

31 August 2017

Sunanda G Dastidar

4

1 reference

31 August 2017

Abhijit Ray

5

1 reference

31 August 2017

language of work or name

English

0 references

publication date

28 April 2014

1 reference

Expert Opinion on Investigational Drugs

31 August 2017

1 reference

31 August 2017

23

1 reference

31 August 2017

7

1 reference

31 August 2017

893-910

1 reference

Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis

31 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.913569

Incidence and prevalence of idiopathic pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.913569

Clinical course and prediction of survival in idiopathic pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.913569

Radiologic findings are strongly associated with a pathologic diagnosis of usual interstitial pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.913569

Idiopathic pulmonary fibrosis: clinical relevance of pathologic classification

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.913569

Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.913569

Corticosteroids and the treatment of idiopathic pulmonary fibrosis. Past, present, and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.913569

Tumor necrosis factor/cachectin plays a key role in bleomycin-induced pneumopathy and fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.913569

Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.913569

Potential role of endothelin-1 in pulmonary fibrosis: from the bench to the clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.913569

Elevated expression of endothelin-1 and endothelin-converting enzyme-1 in idiopathic pulmonary fibrosis: possible involvement of proinflammatory cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.913569

Improvement of bleomycin-induced pulmonary hypertension and pulmonary fibrosis by the endothelin receptor antagonist Bosentan

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.913569

BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.913569

Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.913569

Molecular mechanisms of antifibrotic effect of interferon gamma in bleomycin-mouse model of lung fibrosis: downregulation of TGF-beta and procollagen I and III gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.913569

Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.913569

Delivery and safety of inhaled interferon-γ in idiopathic pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.913569

Colchicine versus prednisone in the treatment of idiopathic pulmonary fibrosis. A randomized prospective study. Members of the Lung Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.913569

Prevention of bleomycin-induced lung fibrosis by aerosolization of heparin or urokinase in rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.913569

Anticoagulant therapy for idiopathic pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.913569

Safety and tolerability of inhaled heparin in idiopathic pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.913569

c-Jun N-terminal kinase 1 is required for the development of pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.913569

Discovery of CC-930, an orally active anti-fibrotic JNK inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.913569

A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.913569

Constitutive activation of 5-lipoxygenase in the lungs of patients with idiopathic pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.913569

Protection from pulmonary fibrosis in leukotriene-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.913569

Pharmacological inhibition of leukotrienes in an animal model of bleomycin-induced acute lung injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.913569

The role of connective tissue growth factor, a multifunctional matricellular protein, in fibroblast biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.913569

Connective tissue growth factor is crucial to inducing a profibrotic environment in "fibrosis-resistant" BALB/c mouse lungs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.913569

Cooperative interaction of CTGF and TGF-β in animal models of fibrotic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.913569

Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.913569

Thalidomide is an inhibitor of angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.913569

Thalidomide prevents bleomycin-induced pulmonary fibrosis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.913569

Thalidomide for the treatment of cough in idiopathic pulmonary fibrosis: a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.913569

Potential Action of IL-4 and IL-13 as Fibrogenic Factors on Lung Fibroblasts in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.913569

Production of interleukin 13 by alveolar macrophages from normal and fibrotic lung

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.913569

Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.913569

Protection from fluorescein isothiocyanate-induced fibrosis in IL-13-deficient, but not IL-4-deficient, mice results from impaired collagen synthesis by fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.913569

Interaction of IL-13 and C10 in the pathogenesis of bleomycin-induced pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.913569

Somatostatin at nanomolar concentration reduces collagen I and III synthesis by, but not proliferation of activated rat hepatic stellate cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.913569

Octreotide regulates CC but not CXC LPS-induced chemokine secretion in rat Kupffer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.913569

Activation of somatostatin receptors attenuates pulmonary fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.913569

The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.913569

From lung injury to fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.913569

Lysyl oxidase: properties, specificity, and biological roles inside and outside of the cell

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.913569

Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.913569

Pirfenidone: antifibrotic agent for idiopathic pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.913569

Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.913569

Pirfenidone in idiopathic pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.913569

Exploratory analysis of a phase III trial of pirfenidone identifies a subpopulation of patients with idiopathic pulmonary fibrosis as benefiting from treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.913569

N-Acetylcysteine--a safe antidote for cysteine/glutathione deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.913569

High-dose acetylcysteine in idiopathic pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.913569

Adenovector-mediated gene transfer of active transforming growth factor-beta1 induces prolonged severe fibrosis in rat lung

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.913569

Re-evaluation of fibrogenic cytokines in lung fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.913569

Progressive transforming growth factor beta1-induced lung fibrosis is blocked by an orally active ALK5 kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.913569

NOX4/NADPH oxidase expression is increased in pulmonary fibroblasts from patients with idiopathic pulmonary fibrosis and mediates TGFbeta1-induced fibroblast differentiation into myofibroblasts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.913569

First in class, potent, and orally bioavailable NADPH oxidase isoform 4 (Nox4) inhibitors for the treatment of idiopathic pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.913569

Aberrant Wnt/beta-catenin pathway activation in idiopathic pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.913569

Bone marrow stem cells expressing keratinocyte growth factor via an inducible lentivirus protects against bleomycin-induced pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.913569

Hepatocyte growth factor is an attractive target for the treatment of pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.913569

Angiotensin II and the fibroproliferative response to acute lung injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.913569

Carbon monoxide induces cytoprotection in rat orthotopic lung transplantation via anti-inflammatory and anti-apoptotic effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.913569

Carbon monoxide has anti-inflammatory effects involving the mitogen-activated protein kinase pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.913569

Carbon monoxide suppresses bleomycin-induced lung fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.913569

ENA-78 is an important angiogenic factor in idiopathic pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.913569

Inhibition of key cytokines by tetrathiomolybdate in the bleomycin model of pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.913569

Vasohibin attenuates bleomycin induced pulmonary fibrosis via inhibition of angiogenesis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.913569

Endostatin, an angiogenesis inhibitor, ameliorates bleomycin-induced pulmonary fibrosis in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.913569

Mechanical stretch up-regulates the B-type natriuretic peptide system in human cardiac fibroblasts: a possible defense against transforming growth factor-β mediated fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.913569

Doxycycline attenuated pulmonary fibrosis induced by bleomycin in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.913569

The role of long-term doxycycline in patients of idiopathic pulmonaryfibrosis: The results of an open prospective trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.913569

Regulation of transforming growth factor-β1-driven lung fibrosis by galectin-3

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.913569

Growth factors in idiopathic pulmonary fibrosis: relative roles

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.913569

BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.913569

Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.913569

Platelet-derived growth factor in idiopathic pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.913569

Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.913569

Imatinib treatment for idiopathic pulmonary fibrosis: Randomized placebo-controlled trial results

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.913569

Peptide-mediated inhibition of mitogen-activated protein kinase-activated protein kinase-2 ameliorates bleomycin-induced pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.913569

PI3K p110γ overexpression in idiopathic pulmonary fibrosis lung tissue and fibroblast cells: in vitro effects of its inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.913569

A phosphoinositide 3-kinase-gamma inhibitor, AS605240 prevents bleomycin-induced pulmonary fibrosis in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.913569

Phosphoinositide 3-kinase γ plays a critical role in bleomycin-induced pulmonary inflammation and fibrosis in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.913569

Occupational and Environmental Risk Factors for Idiopathic Pulmonary Fibrosis: A Multicenter Case-Control Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.913569

Octreotide treatment of idiopathic pulmonary fibrosis: a proof-of-concept study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.913569

10.1517/13543784.2014.913569

21 January 2018

Identifiers

DOI

1 reference

31 August 2017

1 reference